1st Quarter - Amendment

MEDSECUREAN.COM for INDIAN PHARMACEUTICAL ALLIANCE(FORMERLY INDIAN PHARMACEUTICAL ASSOCIATION)

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$15,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
1st Quarter - Report May 10, 2024 $15,000 Replaced
1st Quarter - Amendment (this page) May 10, 2024 $15,000 Replaced
1st Quarter - Amendment Mar 5, 2025 $15,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Derisking the Affordable Medicine Supply Chain (KSMs, APIs), seeking a US-India trade partnership that can be expanded to other trusted allies. Partnership concept includes industry sustainability, quality metrics, market demand, domestic and allied manufacturing, suite of financial tools among others. During this quarter, only engaged in outreach to set up meetings for a CEO delegation Fly-In for Late April.

Foreign entity interest: Indian Pharmaceutical Association is a trade association in India, representing key innovative and affordable medicine manufacturers. These manufacturers supply nearly 50% of Medicare Prescriptions, and of the top 10 US therapeutic categories, the companies supply more than half of the prescriptions for 5 of the top 10 categories-ranging up to 60%.

LobbyistCovered position, as disclosed
KATHLEEN JAEGER New —

Contacted: State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); White House Office; HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR); Natl Security Council (NSC); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS)

Trade (domestic/foreign) TRD

Derisking the Affordable Medicine Supply Chain (KSMs, APIs), seeking a US-India trade partnership that can be expanded to other trusted allies. Partnership concept includes industry sustainability, quality metrics, market demand, domestic and allied manufacturing, suite of financial tools among others. During this quarter, only engaged in outreach to set up meetings for a CEO delegation Fly-In for Late April.

Foreign entity interest: Indian Pharmaceutical Asociation is a trade association in India, representing innovative and affordable medicine manufacturers.

LobbyistCovered position, as disclosed
KATHLEEN JAEGER New —

Contacted: Natl Security Council (NSC); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE; State, Dept of (DOS)

Defense DEF

Derisking the Affordable Medicine Supply Chain (KSMs, APIs), seeking a US-India trade partnership that can be expanded to other trusted allies. Partnership concept includes industry sustainability, quality metrics, market demand, domestic and allied manufacturing, suite of financial tools among others. During this quarter, only engaged in outreach to set up meetings for a CEO delegation Fly-In for Late April.

Foreign entity interest: Indian Pharmaceutical Association is a trade association in India, representing innovative and affordable medicine manufacturers who supply nearly half of the affordable medicine used in the U.S.

LobbyistCovered position, as disclosed
KATHLEEN JAEGER New —

Contacted: Natl Security Council (NSC); Food & Drug Administration (FDA)

Homeland Security HOM

Derisking the Affordable Medicine Supply Chain (KSMs, APIs), seeking a US-India trade partnership that can be expanded to other trusted allies. Partnership concept includes industry sustainability, quality metrics, market demand, domestic and allied manufacturing, suite of financial tools among others. During this quarter, only engaged in outreach to set up meetings for a CEO delegation Fly-In for Late April.

Foreign entity interest: Indian Pharmaceutical Association is a trade association in India, representing innovative and affordable medicine manufacturers who supply the U.S. with nearly 50% of affordable medicine used in the U.S.

LobbyistCovered position, as disclosed
KATHLEEN JAEGER New —

Contacted: Natl Security Council (NSC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.